The vitamin D (VD) receptor (VDR) is extensively expressed in retina. The plasma concentration of 1,25-dihydroxyvitamin D3 has been inversely correlated with the severity of diabetic retinopathy (DR), which raises the possibility that VD, through its antiinflammatory, antioxidant, antiproliferative, and antiangiogenic properties, may protect diabetic retina. The TaqI VDR polymorphism has been associated with severe DR. The FokI VDR polymorphism is a T-to-C substitution in the first codon (f allele), abolishing the first translation initiation site and resulting in a peptide lacking three amino acids (F allele), which increases the transcriptional activity of VDR.
T HE DIABETES CONTROL and Complications Trial has
highlighted that genetic factors could be implicated in the pathogenesis of severe diabetic retinopathy (DR) (1) . Recently, we reported a novel genetic association between the TaqI vitamin D (VD) receptor (VDR) gene polymorphism and risk of severe DR (2) . Several observations suggest that VDR could be a potential candidate gene for DR. The plasma concentration of 1,25-dihydroxyvitamin D3, the active VD, has been inversely correlated with the severity of DR in a Turkish cohort (3) . In addition to its calciotropic function, the VD has potent nonclassical effects, including immunomodulatory, antiinflammatory, antioxidant, antiangiogenic, and antiproliferative properties (4, 5) . All of them are mediated by VDR (6) , a member of the nuclear receptor superfamily, which is extensively expressed in retina (7, 8) .
The FokI VDR gene polymorphism is a functional T-to-C substitution in the first codon (f allele), abolishing the first translation initiation site and resulting in a peptide lacking the first three amino acids (F allele), which increases the transcriptional activity of VDR (9) . This genetic marker can influence, among others, bone mineral density (9) , serum PTH levels (10), susceptibility to prostate cancer (11) , autoimmune diseases (type 1 diabetes, Graves' disease, autoimmune hepatitis, etc.) (12) (13) (14) , insulin secretion (15) , and insulin sensitivity (16) .
To examine whether the functional FokI VDR gene start codon polymorphism is involved in the risk of severe DR, a case-control study was carried out in Caucasian patients with longstanding C-peptide-negative type 1 diabetes.
Subjects and Methods
All patients recruited were unrelated French Caucasian patients living in the Paris area (Ile de France state), belonged to a medium socioeconomic status, and received regular health care. Ethnic minorities living in the Paris area as French Blacks (e.g. Africa), French Polynesian (e.g. Oceanic islands), and patients from French Antillas and Guyana were strictly excluded. All patients were regularly treated in our Department of Diabetology (including the Diabeto-Ophtalmology Unit), at the Hô tel-Dieu Hospital of Paris (France), had type 1 diabetes diagnosed before 35 yr (World Health Organization criteria), C-peptide-negative, and required permanent insulin therapy from the time of diabetes diagnosis. DR was evaluated according to the classification of the EURO-DIAB IDDM Complications Study (17) . The control patients (nonsevere DR group; n ϭ 128) had no DR (level 0; n ϭ 39) or minimal nonproliferative DR (level 1; n ϭ 89), with no antecedent of retinal laser photocoagulation. Patients with advanced DR (severe DR group; n ϭ 126) had panretinal laser photocoagulation secondary to preproliferative DR (level 4; n ϭ 34) or proliferative DR (level 5; n ϭ 92). Individuals with intermediate DR forms, moderate nonproliferative DR (level 2), or severe nonproliferative DR (preproliferative DR) without laser photoco-agulation (level 3) were strictly excluded. DR was evaluated by trained ophthalmologists of the Ophthalmo-Diabetology Unit of our hospital. To avoid diabetic patients being misclassified as having nonsevere DR because of a short duration of diabetes, we selected only control patients with a diabetes duration of more than 15 yr. There was no significant difference in either the mean age of diabetes or the mean duration of diabetes between the two groups. Clinical characteristics of subjects are given in Table 1 . Diabetic nephropathy was assessed by albumin excretion rate (AER): normal AER (Ͻ30 mg/24 h; n ϭ 167), microalbuminuria (30 -300 mg/24 h; n ϭ 43), macroalbuminuria (Ͼ300 mg/24 h; n ϭ 44). To be classified as microalbuminuria or macroalbuminuria, AERs had to be elevated on at least two occasions in the absence of a urinary tract infection. The study was in agreement with the Declaration of Helsinki and had the approval of the ethics committee of our hospital. Informed consent was obtained from all participants. Serum levels of cholesterol, triglycerides, creatinine, and albumin urinary levels were measured by standard laboratory techniques. Serum C-peptide was measured by RIA (Double Antibody C-Peptide kit; Behring, EURO/ DPC Ltd., Gwynedd, UK), and glycosylated hemoglobin (HbA1c) was measured by HPLC method (Diamat; Bio-Rad Laboratories, Inc., Hercules, CA).
Genotyping
Genotypes for FokI VDR polymorphism were scored blindly using PCR-restriction fragment length polymorphism analysis, as previously described (16) . The following primers were used for PCR amplification of exon 2 of the VDR gene: forward 5Ј-AGCTGGCCCTGGCACT-GACTCTGCTCT-3Ј, and reverse 5Ј-ATGGAAACACCTTGCTTCT-TCTCCCTC-3Ј. PCR products were digested with FokI (New England BioLabs, Inc., Beverly, MA) at 37 C for 3 h and then electrophoresed through a 3% agarose gel containing ethidium bromide. FokI digested the first ATG and yielded two products, 69 and 196 bp (f allele), whereas the T to C transition destroyed the FokI site (F allele). The FF and ff genotypes are also named CC and TT, respectively.
Statistical analyses
Data are expressed as means Ϯ sd. The statistical difference in genotype distribution and allele frequencies among the groups was assessed by the 2 test. Where appropriate, the odds ratio (OR) and 95% confidence interval (CI) estimating the relative risks of severe DR associated with FokI VDR polymorphism were calculated. Comparisons between the clinical characteristics of the two groups were made by unpaired t tests. A multivariate logistic regression analysis was performed to assess the independent role of the FokI VDR polymorphism and other variables [sex, age, age at onset, duration of diabetes, body mass index (BMI), blood pressure, HbA1c level, cholesterol level, smoking, renal function] on severe DR. The continuous variables, such as HbA1c and duration, were entered as linear factors after they were tested for nonlinearity by the use of the Box-Tidwell transformation (18) . Because duration of diabetes is a crucial factor to be controlled in genetic studies of diabetic complications (19) , the influence of FokI polymorphism on the risk of severe DR was analyzed according to different cutoffs of diabetes duration (e.g. control and case patients were stratified by mean diabetes duration, Ͻ25 and Ն25 yr). Taking the f allele frequency of 34% (20) and an OR of 2.5, this sample provided more than 95% power to detect an association (P Ͻ 0.05). Two-sided P Ͻ 0.05 was regarded as significant. Data analyses were performed with StatView version 4 (Abacus Concepts, Inc., Berkeley, CA). Taking into account that FokI single nucleotide polymorphism (SNP) can affect insulin sensitivity (16) and especially insulin secretion (15), we analyzed mediation models, using the tests of Sobel and Goodman (21) , to detect whether a fraction of the influence of FokI VDR polymorphism on severe DR is mediated by HbA1c levels (program for Statistical Package for the Social Sciences, version 12.0 for Windows; SPSS, Inc., Chicago, IL). Mediation refers to the covariance relationships among three variables: an independent variable (IV), a potential mediating variable, and a dependent variable (DV). Mediation can be said to occur when the IV (FokI SNP) significantly affects the mediator (HbA1c levels), the IV significantly affects the DV (severe DR) in the absence of the mediator, the mediator has a significant unique effect on the DV, and the effect of the IV on the DV shrinks upon the addition of the mediator to the model (21) .
Results

FokI VDR polymorphism and severe DR
Clinical characteristics of the study and control groups are given in Table 1 . Genotype distributions in whole sample and in both study and control groups were in Hardy-Weinberg equilibrium (P ϭ 0.99, P ϭ 0.87, and P ϭ 0.98, respectively) and did not differ between genders (P ϭ 0.33, P ϭ 0.26, and P ϭ 0.82, respectively). The genotype distribution was FF, 37.4% (n ϭ 95); Ff, 47.6% (n ϭ 121); and ff, 15.0% (n ϭ 38).
The distribution of FokI polymorphism was significantly different between groups ( 2 ϭ 6.138; df ϭ 2; P ϭ 0.047). The frequency of FF genotype was significantly higher in individuals with mild or absent DR (n ϭ 57; 44.5%) than in patients with severe DR (n ϭ 38, 30.2%, 2 ϭ 5.602, df ϭ 1, OR ϭ 0.54, 95% CI 0.32-0.90, P ϭ 0.018, corrected P ϭ 0.025). The frequency of F allele was significantly higher in the control (n ϭ 170; 66.4%) than in the study group (n ϭ 141, 56.0%, 2 ϭ 5.846, df ϭ 1, OR ϭ 0.64, 95% CI 0.44 -0.92, P ϭ 0.016, corrected P ϭ 0.020). The genotype and allele frequencies between groups are summarized in Table 2 . Clinical 51 , P ϭ 0.0006), macroalbuminuria (OR ϭ 14.60, 95% CI 3.14 -67.77), P ϭ 0.0006), HbA1c levels (OR ϭ 1.89, 95% CI 1.42-2.51, P Ͻ 0.0001), and diastolic blood pressure (OR ϭ 1.07, 95% CI 1.02-1.12, P ϭ 0.0034) were the only IVs for severe DR (Table 3) .
Effect of duration of diabetes mellitus
Among case (n ϭ 67) and control (n ϭ 67) patients who had had diabetes for less than 25 yr (median value), the association between severe DR and FokI polymorphism was strongly increased ( 2 test ϭ 11.447; df ϭ 2; P ϭ 0.003; Table 4 ). All groups were in Hardy-Weinberg equilibrium (P Ͼ 0.5).
Among case (n ϭ 59) and control (n ϭ 61) patients with diabetes duration Ն 25 yr, the FokI polymorphism was not associated with severe DR ( 2 test ϭ 3.270; df ϭ 2; P ϭ 0.20; Table 4 ). All groups were in Hardy-Weinberg equilibrium (P Ͼ 0.25).
We observed a significant interaction between diabetes duration and the association between FokI polymorphism and severe DR (P for interaction ϭ 0.016).
FokI VDR polymorphism and HbA1c levels
In the whole sample (n ϭ 254), the distribution of FokI polymorphism was not associated with HbA1c levels (ANOVA F ϭ 0.69; P ϭ 0.51).
Of note, among patients with diabetes duration of less than 25 yr (n ϭ 134), the FokI polymorphism was significantly associated with HbA1c levels (ANOVA F ϭ 3.82; P ϭ 0.024). Specifically, FF-carriers had significantly lower HbA1c levels (8.28 Ϯ 1.52%) than ff-carriers (9.34 Ϯ 1.71%; P ϭ 0.0073), and Ff-carriers had significantly lower HbA1c levels (8.50 Ϯ 1.48%) than ff-carriers (P ϭ 0.026). Also, among patients with diabetes of less than 30 yr (n ϭ 187), FF-carriers had significantly lower HbA1c levels (8.30 Ϯ 1.50%) than ff-carriers (9.01 Ϯ 1.82%; P ϭ 0.039).
According to the tests of Sobel and Goodman, in patients with diabetes duration less than 25 yr, HbA1c mediates 30.48% (P ϭ 0.025) of the effects of FokI VDR SNP on severe DR (ratio of the indirect to the direct effect ϭ 0.44). Contrary, in patients with diabetes duration of 25 yr or more, HbA1c only mediates 15.96% (P Ͼ 0.30) of the effects of FokI VDR SNP on severe DR (ratio of the indirect to the direct effect ϭ 0.19). For the continuous variables, OR was calculated by logistic regression per unit of change of measurement used (e.g., HbA1c, 1%; systolic blood pressure, 1 mm Hg, etc.). Multivariate logistic regression analysis using only those variables that were significant in univariate logistic regression showed similar results (data not shown).
FokI VDR polymorphism and diabetic nephropathy
The distribution of FokI polymorphism was not different among normoalbuminuric, microalbuminuric, and albuminuric patients ( 2 ϭ 2.467; df ϭ 4; P ϭ 0.
65). Diabetes duration did not influence this result (data not shown).
Discussion
This is the first report that demonstrates a significant association between the FokI VDR gene polymorphism and the risk of advanced DR, in Caucasian patients with C-peptidenegative type 1 diabetes, especially among those patients with a duration of diabetes less than 25 yr. Specifically, patients carrying the F allele (or FF genotype) had a significantly lower prevalence of advanced DR. This finding was confirmed in multivariate statistical models.
Our findings are supported by several clinical and experimental observations. VD has osteocalcic, immunomodulatory, antiinflammatory, antioxidant, antiangiogenic, and antiproliferative functions in many kinds of cells, at both pharmacological and physiological levels (4 -6). VD administration reduces angiogenesis, proliferation, and tumor size of retinoblastoma (22) (23) (24) , and corneal inflammation and neovascularization (25) (26) (27) . The plasma concentration of VD has been inversely correlated with the severity of DR (3). VDR is extensively expressed in retina (7, 8) . VD increases insulin sensitivity and insulin secretion (28) , and hyperglycemia down-regulates VDR (29) and renal 25-hydroxyvitamin D3-1 ␣-hydroxylase (30), the rate-limiting enzyme in the bioactivation of VD. Of note, the FF genotype of FokI VDR gene polymorphism has been associated with higher insulin secretion and insulin sensitivity, in nondiabetic Bangladeshi adults with VD insufficiency (15) and healthy Caucasians (16), respectively. We have reported a significant association between the T allele of TaqI VDR polymorphism and lower risk of advanced DR, especially among patients with long duration of diabetes and poor glycemic control (2) . In nondiabetic Bangladeshi adults, both TT TaqI and FF FokI genotypes have been associated with the highest VDR mRNA copy numbers by 25.8% and 19.7%, compared with tt and ff genotypes (15) .
Because the FF genotype (or F allele) of FokI polymorphism has been associated with increased transcriptional activity of VDR in most (9, 15, 31, 32), but not all, studies (33), we hypothesize that potential beneficial effects of VD on retina (e.g. immunomodulatory, antiinflammatory, antioxidant, antiangiogenic, and antiproliferative properties) were higher in patients carrying the F allele than in f-carrier patients, thus explaining the significant association between F allele and lower risk of advanced DR. In addition, we postulate that this finding was strongly increased in patients with a duration of diabetes less than 25 yr, in part because, among these individuals, but not in the whole sample, we detected significantly lower HbA1c levels in FF-carrier than in ff-carrier patients. Moreover, the Sobel and Goodman tests confirmed that, among patients with diabetes duration less than 25 yr, HbA1c mediated 30.48% of the effects of FokI VDR SNP on severe DR but only 15.96% among those patients with diabetes duration of 25 yr or more. This is in accordance with the fact that the FF genotype has been associated with both higher insulin secretion (15) and higher insulin sensitivity (16) . Indeed, the duration of diabetes is a crucial factor to be controlled in genetic studies of diabetic complications (19) . A susceptibility allele would be more strongly associated with affected individuals with a short duration, rather than a long duration, of diabetes (19, 34) . Unquestionably, among patients with severe DR, despite the absence of one of the most important environmental factors (long duration of diabetes), other environmental factors (e.g. high HbA1c levels) as well as genetic factors must be overexpressed (e.g. FokI VDR SNP). The chance of spurious findings due to survival bias is unlikely, because we studied relatively young individuals. Indeed, there is no report showing an association between this polymorphism and heart disease.
We cannot exclude the possibility that the FokI VDR polymorphism site is a marker of a nearby functional polymorphism within the VDR gene or a nearby gene. Nevertheless, it has been reported among 68 VDR SNPs, including classical 3Ј polymorphisms (e.g. TaqI SNP, BsmI SNP, etc.), that FokI SNP, which is located in a 1.3-kb LD-breaking spot between two LD blocks, is the only SNP that has no detectable LD with any other SNP and cannot be assigned to any LD block in VDR (35) . This scenario is supported by LD reports (www.hapmap.org) from the HapMap International Project (36) . Thus, the FokI SNP could be the truly pathogenic VDR polymorphism for severe DR. On the other hand, the independence of FokI SNP can explain why haplotype-based analysis (combined effect of FokI and TaqI VDR SNPs) were not informative in our cohort (data not shown).
It is not surprising that, whereas the association of the FokI VDR SNP with severe DR was especially important among patients with a short duration of diabetes (Ͻ25 yr), a previous report showed that TaqI VDR SNP was preferentially associated with severe DR among patients with a long duration of diabetes (Ͼ25 yr). Taking into account that DR is a consequence of interactions between environmental and genetics factors, we hypothesize that, when the genetic influence is mild (the TaqI SNP appears to have only a mild or no effect on VDR) (37), the environmental exposure is stronger (long duration of diabetes). In the opposite picture, when the genetic participation is higher (the FokI SNP is the only VDR polymorphism that intensively affects the protein structure of VDR) (37), the development and progression of DR will require a lower environmental exposure (short duration of diabetes). This viewpoint is supported by multiple studies that have reported associations between important genetic alterations (e.g. deletions) and early onset of several conditions (38 -40) . This view requires further confirmation in prospective studies.
In molecular terms, VD can reduce nitric oxide production via inducible nitric oxide synthase down-regulation (41), inhibit vascular endothelial growth factor (VEGF) induced endothelial cell proliferation (42) , down-regulate the IGF-I pathway (43) , up-regulate the cellular transporters of sulfate (44) which are negative regulators of angiogenesis (45), down-regulate the renin-angiotensin system (46) , stimulate the TGF␤-1 (an antiproliferative and proapoptotic molecule) (47) , and inhibit multiple proinflammatory and proangiogenic cytokines (4 -6, 25-27) . All of these molecules have been implicated in the pathogenesis of DR. On the other hand, calcium homeostasis and calcium-dependent signaling pathways have an important role in the development of retinal hypoxia (48), a major process in severe DR.
Can VD represent a major molecular link between kidney and retina? Patients with diabetic nephropathy have both a high risk of DR (49) and a high risk of low VD status (50) . On the other hand, VD deficiency is associated with high plasma PTH levels. Contrary to VD, PTH excess can reduce glucose tolerance (51) and induce inflammatory cytokines (52) . Interestingly, PTH is present in subretinal fluids of the human eye, and it was found high plasma PTH 44 -68 levels (up to 4000 pg/ml) in patients with rhegmatogenous retinal detachments, especially among those with longstanding disease and proliferative vitreoretinopathy, including proliferative DR (53) . Interestingly, a Czech study reported that serum PTH values were statistically higher in the ff than in the FF FokI VDR genotypes among Caucasian women with normal serum PTH levels (10).
At last, because human endothelia are able to produce active VD, in part via the rapid induction of endothelial 1␣-OHase activity by inflammatory cytokines (54) , potential local VD production in retinal endothelial cells is not unlikely and deserves to be investigated.
In conclusion, we have reported a novel association between the functional FokI VDR gene polymorphism and the risk of advanced DR in a well-characterized Caucasian cohort of patients with C-peptide-negative type 1 diabetes, especially among those patients with a duration of diabetes less than 25 yr, supported by a previous report showing an association between TaqI VDR polymorphism and severe DR.
